SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.897
AS - Asia 4.545
EU - Europa 3.402
SA - Sud America 690
AF - Africa 60
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 20.607
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.669
SG - Singapore 1.681
CN - Cina 1.597
DE - Germania 776
BR - Brasile 626
UA - Ucraina 614
IT - Italia 508
HK - Hong Kong 457
GB - Regno Unito 405
TR - Turchia 399
FI - Finlandia 343
SE - Svezia 172
RU - Federazione Russa 144
CA - Canada 112
PL - Polonia 100
VN - Vietnam 99
MX - Messico 96
FR - Francia 95
ID - Indonesia 79
IN - India 72
AT - Austria 60
BE - Belgio 51
JP - Giappone 43
ES - Italia 34
ZA - Sudafrica 33
NL - Olanda 31
BD - Bangladesh 28
LT - Lituania 26
AR - Argentina 25
IQ - Iraq 14
IR - Iran 11
PK - Pakistan 11
EC - Ecuador 10
EG - Egitto 10
PE - Perù 9
CO - Colombia 8
CZ - Repubblica Ceca 8
AU - Australia 7
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
IE - Irlanda 5
IL - Israele 5
JO - Giordania 5
MA - Marocco 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
CH - Svizzera 4
KE - Kenya 4
KG - Kirghizistan 4
PY - Paraguay 4
RO - Romania 4
VE - Venezuela 4
DK - Danimarca 3
DZ - Algeria 3
HN - Honduras 3
JM - Giamaica 3
LV - Lettonia 3
NO - Norvegia 3
PA - Panama 3
PH - Filippine 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BH - Bahrain 2
CL - Cile 2
CR - Costa Rica 2
DM - Dominica 2
EE - Estonia 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
KH - Cambogia 2
KR - Corea 2
KZ - Kazakistan 2
NP - Nepal 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
KY - Cayman, isole 1
LK - Sri Lanka 1
NI - Nicaragua 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 20.607
Salva come PNG Salva come JPEG
Città #
Fairfield 1.266
Ashburn 1.257
Woodbridge 1.234
Singapore 990
Houston 698
Jacksonville 672
Chandler 666
Beijing 632
Santa Clara 576
Ann Arbor 517
Seattle 478
Hong Kong 454
Wilmington 450
Cambridge 415
Munich 365
Dallas 263
Izmir 237
Nanjing 173
Ferrara 167
Princeton 165
Los Angeles 164
New York 153
Helsinki 142
San Diego 114
Boardman 105
Shanghai 100
Warsaw 91
Milan 89
Jakarta 70
Bremen 66
Mexico City 59
São Paulo 58
Turku 58
Shenyang 57
London 52
Brussels 50
Falls Church 48
Hebei 45
Hefei 45
Vienna 44
Moscow 43
The Dalles 43
Tianjin 43
Buffalo 41
Brooklyn 40
Ho Chi Minh City 39
Tokyo 39
Nanchang 38
Chicago 37
Frankfurt am Main 37
Boston 34
Montreal 33
Toronto 31
Atlanta 30
Changsha 30
Jiaxing 29
Norwalk 29
Denver 28
Orem 26
Chennai 25
San Mateo 25
Stockholm 25
Washington 25
Auburn Hills 24
Poplar 24
San Francisco 24
Johannesburg 23
Jinan 22
Mountain View 21
Rio de Janeiro 21
Falkenstein 20
Redwood City 20
Hanoi 19
Manchester 18
Ankara 17
Dearborn 17
Rome 17
Zhengzhou 17
Charlotte 15
Ottawa 15
Phoenix 15
Brasília 14
Council Bluffs 14
Guangzhou 14
Orange 14
Leawood 13
Mcallen 13
Querétaro 13
Belo Horizonte 12
Lappeenranta 12
Montréal 12
New Delhi 12
Nuremberg 12
Roubaix 12
Secaucus 12
Addison 11
Augusta 11
Columbus 11
Hangzhou 11
Redmond 11
Totale 14.638
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 334
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 323
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 267
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 226
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 225
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 214
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 212
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 209
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 198
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 195
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 193
5‐Hydroxytryptamine‐mediated effects of nicotine on endogenous GABA efflux from guinea‐pig cortical slices 191
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 191
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 189
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 187
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 183
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 182
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 182
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 182
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 180
Loss of cortical GABA terminals in Unverricht–Lundborg disease 175
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 174
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 173
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 172
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 171
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 170
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 169
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 168
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 167
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 165
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 165
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 164
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 163
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]‐d‐aspartate and endogenous GABA in freely moving guinea‐pigs 163
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 163
Role of LRRK2 in the regulation of dopamine receptor trafficking 163
Antagonisti dei recettori NOP e loro usi terapeutici 162
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 161
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 161
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 160
Autophagy and LRRK2 in the Aging Brain 160
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 160
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 158
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 158
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 157
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 157
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 157
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 156
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 156
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 156
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 155
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 154
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 153
NOP receptor ligands and Parkinson’s disease 153
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 151
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 150
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 149
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 147
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 146
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 145
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 144
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 143
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 143
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 143
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 143
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 141
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 138
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 138
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 136
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 135
Parkinson's disease: no NOP, new hope 135
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 133
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 132
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 131
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat 129
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 129
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 129
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 127
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 124
Managing Parkinson's disease: moving ON with NOP 124
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 123
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 122
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 120
Synthesis and structure activity relationships of delthorphine analogues 117
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 117
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 117
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 115
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 115
null 113
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 113
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 112
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 112
NR2A and NR2B Subunit Selective NMDA antagonists improve motor performance and reduce pallidal GABA release in 6-OHDA hemilesioned rats 112
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 110
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 110
null 108
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 108
Nociceptin/orphanin FQ modulates neurotransmitter release in the substantia nigra: Biochemical and behavioural outcome 108
Nociceptin/orphanin FQ receptor antagonists reverse parkinsonism in MPTP-treated mice and non-human primates 106
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 102
Totale 15.627
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.137
Totale 104.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.350 0 0 0 0 111 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20253.708 74 88 310 82 402 505 146 204 569 373 528 427
2025/20264.572 1.178 343 893 1.354 804 0 0 0 0 0 0 0
Totale 20.824